Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mixed salts of a single-entity amphetamine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Mixed salts of a single-entity amphetamine | DRUG | - |
| Atomoxetine hydrochloride | DRUG | - |
Inclusion Criteria: * primary diagnosis of ADHD * not naive to pharmacologic ADHD treatment * valid driver's license with a minimum of 3 years driving experience Exclusion Criteria: * recent history of drug dependence or substance use disorder * any specific cardiac condition that would, in the o...
Mixed salts of a single-entity amphetamine is used for Attention Deficit Disorder With Hyperactivity (ADHD). It is a small molecule being developed by Takeda Pharmaceutical Company Limited. The drug is currently in Phase 3 clinical development for this indication.
Takeda Pharmaceutical Company Limited (ticker: TAK) is the developer of Mixed salts of a single-entity amphetamine. The drug is being studied for the treatment of Attention Deficit Disorder With Hyperactivity. It is currently in Phase 3 clinical trials.
Mixed salts of a single-entity amphetamine is in Phase 3 clinical development. It is an investigational drug being studied for Attention Deficit Disorder With Hyperactivity. The drug has completed one Phase 3 trial and is not yet approved.
Mixed salts of a single-entity amphetamine has one completed Phase 3 trial, NCT00557960. This trial compared the drug and atomoxetine hydrochloride to placebo on simulated driving safety and cognitive functioning in adults with ADHD. The study enrolled 36 participants in the United States.
Mixed salts of a single-entity amphetamine is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for Attention Deficit Disorder With Hyperactivity. The drug has completed one Phase 3 trial but has not received regulatory approval.